Decreased Exhaled Nitric Oxide in Mild Persistent Asthma Patients Treated with a Leukotriene Receptor Antagonist, Pranlukast.

Abstract

Exhaled nitric oxide (NO) level decreases after corticosteroid treatment in asthmatics, but the effect of a leukotriene receptor antagonist, pranlukast, on exhaled NO has not been elucidated. Pranlukast treatment in mild persistent asthmatics for 4 weeks decreased the exhaled NO level, which did not differ from the levels in healthy subjects.